CA Patent

CA3105501A1 — Selective estrogen receptor degraders

Assigned to Eli Lilly and Co · Expires 2020-01-16 · 6y expired

What this patent protects

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, -CF3, or -CH3, and the other is hydrogen, and methods f…

USPTO Abstract

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, -CF3, or -CH3, and the other is hydrogen, and methods for their use are provided.

Drugs covered by this patent

Patent Metadata

Patent number
CA3105501A1
Jurisdiction
CA
Classification
—
Expires
2020-01-16
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.